Upadacitinib and Cariprazine: Interaction Details
AI-assisted, pharmacist-reviewed · AI content regenerated Jul 16, 2026 · Source data updated Jul 16, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Cariprazine
Upadacitinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
Here's what's going on. Cariprazine (Vraylar) is broken down and turned into its active forms by a liver enzyme called CYP3A4. Upadacitinib (Rinvoq) can mildly speed up that same enzyme. Because this enzyme both makes and clears cariprazine's active pieces, no one can say for sure whether taking these together makes cariprazine stronger or weaker. That's why they aren't usually recommended together.
The good news is this is very manageable. If both drugs are on your list, don't stop either one on your own. Just check in with your pharmacist or doctor, who can watch how you're doing and adjust your plan if needed.
Mechanism: Cariprazine is a CYP3A4 substrate; CYP3A4 mediates both formation and elimination of its active metabolites (DCAR, DDCAR). Upadacitinib is a weak CYP3A4 inducer.
- Direction: Net effect on cariprazine exposure is unclear, since the enzyme drives both activation and clearance.
- Magnitude: Not quantified; not formally studied.
- Evidence: Theoretical.
- Onset: Unspecified.
Management: Concurrent use is not recommended per labeling. If combined, monitor clinically for altered antipsychotic efficacy and for adverse effects; the cariprazine dose may need to be individualized by the care team. Consider an alternative if feasible.
What happens
Effects on the cariprazine exposure has not been evaluated and the net effect is unclear
Interaction Deep Dive
Giving cariprazine (which is metabolized by CYP3A4) together with a CYP3A4 inducer is not advised. The generation as well as the clearance of cariprazine's active metabolites depends on CYP3A4. How CYP3A4 inducers influence cariprazine exposure has not been studied, so the overall outcome remains uncertain1.
Why it happens (mechanism)
Induction of CYP3A4-mediated metabolism of cariprazine
How to manage this interaction
What your care team may do:
- Because combining these is generally not recommended, they may consider whether a different medication could work in place of one of them.
- If you do take both, they can monitor you more closely, watching whether your Vraylar seems to be working as expected and checking for any side effects.
- Your cariprazine dose may need to be adjusted and individualized by your care team.
What you should do: Keep taking both exactly as prescribed, and let your pharmacist or prescriber know you are on both so they can tailor your plan.
Management is individual — confirm any change with your pharmacist or prescriber.
Common questions
Can I take Upadacitinib and Cariprazine together?
Combining cariprazine (Vraylar) with upadacitinib (Rinvoq) isn't generally recommended because the net effect on cariprazine is unpredictable; keep taking both as prescribed and ask your pharmacist or doctor to review it. Always confirm with your pharmacist or prescriber before making any change.
How serious is the Upadacitinib and Cariprazine interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How is the Upadacitinib and Cariprazine interaction managed?
What your care team may do: Because combining these is generally not recommended, they may consider whether a different medication could work in place of one of them. If you do take both, they can monitor you more closely, watching whether your Vraylar seems to be working as expected and checking for any side effects. Your cariprazine dose may need to be adjusted and individualized by your care te… Management is individual — always follow your own care team's guidance.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Upadacitinib or Cariprazine need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: VRAYLAR(R) oral capsules, cariprazine oral capsules. AbbVie Inc. (per FDA), North Chicago, IL, 2024. DailyMed
Keep reading about Cariprazine
Keep reading about Upadacitinib
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist